Skip to main content
Year archive

OPKO Health Inc. — 2025 filings

All 141 regulatory filings released by OPKO Health Inc. (OPK) in 2025, sourced directly from the official regulator.

141 Filings
2025 Period
2025 filings (141)
Filing Released Lang
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing
2025-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Regulatory Filings
2025-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing
2025-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Regulatory Filings
2025-11-23 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing
2025-11-20 Hebrew (modern)
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D ET AL
Director's Dealing
2025-11-20 English
OPKO Health to participate in the Piper Sandler 37th Annual Healthcare Conference.
Regulatory Filings
2025-11-20 Hebrew (modern)
OPKO Health to participate in the Piper Sandler 37th Annual Healthcare Conference.
Regulatory Filings
2025-11-20 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- PHILLIP FROST
Director's Dealing
2025-11-19 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- PHILLIP FROST
Regulatory Filings
2025-11-19 English
Immediate Report
Director's Dealing
2025-11-01 English
Immediate Report
Regulatory Filings
2025-11-01 English
Report of Periodic or Interim Report
Interim / Quarterly Report 9M 2025
2025-10-29 English
Report of Periodic or Interim Report
Report Publication Announcement
2025-10-29 English
Immediate Report
Earnings Release Q3 2025
2025-10-29 English
Immediate Report
Earnings Release Q3 2025
2025-10-29 English
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
M&A Activity
2025-10-29 English
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
Regulatory Filings
2025-10-29 English
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
Regulatory Filings
2025-10-28 English
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
Regulatory Filings
2025-10-28 English
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Report Publication Announcement
2025-10-23 English
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Report Publication Announcement
2025-10-23 English
Immediate Report
Major Shareholding Notification
2025-10-02 English
Immediate Report
Director's Dealing
2025-10-02 English
Labcorp completes acquisition of select assets of BioReference.
M&A Activity
2025-09-16 English
Labcorp completes acquisition of select assets of BioReference.
Regulatory Filings
2025-09-16 English
Immediate Report
Director's Dealing
2025-08-19 English
Immediate Report
Regulatory Filings
2025-08-19 English
Immediate Report
Director's Dealing
2025-08-09 English
Immediate Report
Report Publication Announcement
2025-08-09 English
Report of Periodic or Interim Report
Report Publication Announcement Q2 2025
2025-07-31 English
Immediate Report
Earnings Release Q2 2025
2025-07-31 English
Immediate Report
Report Publication Announcement
2025-07-31 English
Immediate Report
Earnings Release Q2 2025
2025-07-31 English
Immediate Report
Report Publication Announcement
2025-07-31 English
Immediate Report
Report Publication Announcement
2025-07-26 English
Immediate Report
Report Publication Announcement
2025-07-26 English
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Regulatory Filings
2025-07-08 English
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
Report Publication Announcement
2025-07-08 English
to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
Report Publication Announcement
2025-06-25 English
to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
Regulatory Filings
2025-06-25 English
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meetin
Regulatory Filings
2025-06-25 English
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meetin
Report Publication Announcement
2025-06-25 English
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Board/Management Information
2025-06-09 English
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
Report Publication Announcement
2025-06-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Elias Zerhouni, M.D.
Director's Dealing
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Elias Zerhouni, M.D.
Director's Dealing
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Steven D. Rubin
Director's Dealing
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF F SECURITIES-Gary J. Nabel, M.D., Ph.D
Director's Dealing
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Director's Dealing
2025-05-30 English
CHANGES IN BENEFICIAL OWNERSHIP-FORM 4-Adam Logal
Report Publication Announcement
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D.
Director's Dealing
2025-05-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Jane H. Hsiao, Ph.D.
Director's Dealing
2025-05-30 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-05-30 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-05-30 English
Form 8-K-Compensation for the Company’s executive officers
Remuneration Information
2025-05-30 English
Form 8-K-Compensation for the Company’s executive officers
Remuneration Information
2025-05-30 English
OPKO Health to Participate in Two Upcoming Investor Conferences
Report Publication Announcement
2025-05-15 English
OPKO Health to Participate in Two Upcoming Investor Conferences
Report Publication Announcement
2025-05-15 English
FORM 10-Q-For the quarterly period ended March 31, 2025
Interim / Quarterly Report Q1 2025
2025-05-02 English
FORM 10-Q-For the quarterly period ended March 31, 2025
Report Publication Announcement
2025-05-02 English
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
Earnings Release Q1 2025
2025-05-02 English
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
Earnings Release Q1 2025
2025-05-02 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Alice Lin-Tsing Yu, M.D., Ph.D
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Alice Lin-Tsing Yu, M.D., Ph.D
Report Publication Announcement
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard C. Pfenniger, Jr
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard C. Pfenniger, Jr
Report Publication Announcement
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-John A. Paganell
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-John A. Paganell
Report Publication Announcement
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Roger J. Medel, M.D
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Roger J. Medel, M.D
Report Publication Announcement
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Prem A. Lachman, M.D
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Prem A. Lachman, M.D
Report Publication Announcement
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard M. Krasno, Ph.D
Director's Dealing
2025-04-23 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Richard M. Krasno, Ph.D
Report Publication Announcement
2025-04-23 English
results of annual meeting held on April 23, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-04-23 English
results of annual meeting held on April 23, 2025
Report Publication Announcement
2025-04-23 English
Health to Report First Quarter 2025 Financial Results on April 30, 2025, a conference callon April 30th beginning at 4:30 p.m. Eastern time
Earnings Release Q1 2025
2025-04-17 English
Health to Report First Quarter 2025 Financial Results on April 30, 2025, a conference callon April 30th beginning at 4:30 p.m. Eastern time
Report Publication Announcement
2025-04-17 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-04-14 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Regulatory Filings
2025-04-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-04-09 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-04-09 English
OPKO has authorized an increase of $100 million to the Company’s existing common stock repurchase program
Transaction in Own Shares
2025-04-05 English
OPKO has authorized an increase of $100 million to the Company’s existing common stock repurchase program
Transaction in Own Shares
2025-04-05 English
Schedule 13D - Hsiao JANE PH D
Major Shareholding Notification
2025-04-05 English
Schedule 13D - Hsiao JANE PH D
Director's Dealing
2025-04-05 English
Schedule 13D-Phillip Frost, M.D
Transaction in Own Shares
2025-04-05 English
Schedule 13D-Phillip Frost, M.D
Major Shareholding Notification
2025-04-05 English
Form 13G - OPKO Health Inc. holdings of Entera Bio Ltd.
Major Shareholding Notification
2025-04-03 English
Form 13G - OPKO Health Inc. holdings of Entera Bio Ltd.
Director's Dealing
2025-04-03 English
Form4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Director's Dealing
2025-04-02 English
Form4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-04-02 English
Form 8-K-OPKO entered into an additional exchange agreements pursuant to which noteholders have agreed to exchange notes for shares and cash.
Regulatory Filings
2025-04-02 English
Form 8-K-OPKO entered into an additional exchange agreements pursuant to which noteholders have agreed to exchange notes for shares and cash.
Report Publication Announcement
2025-04-02 English
Form4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Director's Dealing
2025-03-29 English
Form4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-03-29 English
Form 8-K-entered into exchange agreements pursuant to which noteholders have agreed to exchange notes for shares and cash
Share Issue/Capital Change
2025-03-29 English
Form 8-K-entered into exchange agreements pursuant to which noteholders have agreed to exchange notes for shares and cash
Report Publication Announcement
2025-03-29 English
Amendment No. 1 on Form 10-K/A to amend its Annual Report on Form 10-K for the year ended December 31, 2024 originally filed on March 3, 2025.
Annual Report FY 2024
2025-03-22 English
Amendment No. 1 on Form 10-K/A to amend its Annual Report on Form 10-K for the year ended December 31, 2024 originally filed on March 3, 2025.
Report Publication Announcement
2025-03-22 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-03-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-03-18 English
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Regulatory Filings
2025-03-17 English
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Report Publication Announcement
2025-03-17 English
Proxy Statement for the 2025 Annual Meeting of Stockholders to be held on April 23, 2025
Proxy Solicitation & Information Statement
2025-03-15 English
Proxy Statement for the 2025 Annual Meeting of Stockholders to be held on April 23, 2025
Remuneration Information
2025-03-15 English
Notice of the 2025 Annual Meeting of Stockholders to be held on April 23, 2025
AGM Information
2025-03-15 English
Notice of the 2025 Annual Meeting of Stockholders to be held on April 23, 2025
Remuneration Information
2025-03-15 English
2024 Annual Report on Form 10-K
Annual Report FY 2024
2025-03-15 English
2024 Annual Report on Form 10-K
Report Publication Announcement FY 2024
2025-03-15 English
Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses
M&A Activity
2025-03-11 English
Labcorp Announces Acquisition of Select Assets of BioReference Health’s Innovative Oncology and Related Clinical Testing Services Businesses
Report Publication Announcement
2025-03-11 English
FORM 8-K- BioReference and Buyer entered into an Asset Purchase Agreement
Regulatory Filings
2025-03-11 English
FORM 8-K- BioReference and Buyer entered into an Asset Purchase Agreement
Regulatory Filings
2025-03-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-03-05 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-03-05 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost
Director's Dealing
2025-03-04 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost
Director's Dealing
2025-03-04 English
Annual Report on Form 10-K for the year ended December 31, 2024
Annual Report FY 2024
2025-03-03 English
Annual Report on Form 10-K for the year ended December 31, 2024
Report Publication Announcement FY 2024
2025-03-03 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost, M.D., ET AL
Director's Dealing
2025-03-01 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-03-01 English
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial
Earnings Release Q4 2024
2025-02-28 English
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial
Report Publication Announcement Q4 2024
2025-02-28 English
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
Earnings Release Q4 2024
2025-02-14 English
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025
Regulatory Filings
2025-02-14 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-hillip Frost, M.D., ET AL
Director's Dealing
2025-01-29 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-hillip Frost, M.D., ET AL
Director's Dealing
2025-01-29 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES - Phillip Frost
Director's Dealing
2025-01-18 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES - Phillip Frost
Report Publication Announcement
2025-01-18 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Director's Dealing
2025-01-16 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Phillip Frost, M.D., ET AL
Report Publication Announcement
2025-01-16 English
COMPANY'S PRESENTATION,J.P. Morgan Healthcare Conference
Investor Presentation
2025-01-16 English
COMPANY'S PRESENTATION,J.P. Morgan Healthcare Conference
Report Publication Announcement
2025-01-16 English
To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2025-01-10 English
To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Report Publication Announcement
2025-01-10 English
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Regulatory Filings
2025-01-07 English
OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck
Report Publication Announcement
2025-01-07 English